GLABF · Gemina Laboratories Ltd.
Market Cap
$3.83M
Shares
76.57M
Volume · Dec 31
266.36K
Avg daily vol (11 sessions)
127.02K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.05
Open$0.06
Day$0.04–0.06
Available close range$0.04–0.92
Avg vol 30d53K
Short int8K · 0.0% of shares · 1.0d
Short vol66%
DataMar 2022–Dec 2025
The closing range uses available history since Jan 21, 2025; less than a full year is stored.
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-90.8%
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.72
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−90%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−91%
trailing
6-month return
−86%
trailing
YTD return
−91%
this year
Relative strength
−95%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.01% of shares out · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
2530%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
127.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−90%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.01% of shares out · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Range low $0
Now $0 · 1%
Range high $1
vs 50-day avg -90%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GLABF
this stock
Gemina Laboratories Ltd.
|
$3.83M | — | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$137.57B | +19.7% | +46.2% | 34.9 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.40B | +23.2% | +20.8% | 21.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$93.61B | +684.5% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GLABF | -44.4% | -90.9% | -85.6% | -70.6% | -90.9% |
| SPY | -0.9% | +0.1% | +9.4% | -0.2% | +16.4% |
| vs SPY | -43.6% | -91.0% | -95.0% | -70.4% | -107.2% |